BioAge Labs, Inc.
Business
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic candidates for metabolic diseases by targeting human aging biology. The company's lead program, BGE-102, is a small-molecule NLRP3 inflammasome inhibitor in Phase 1 development for cardiometabolic disease and diabetic macular edema. BioAge also develops apelin receptor APJ agonists for obesity treatment and advances platform-derived programs through collaborations with Eli Lilly and Novartis. The company leverages proprietary longitudinal human aging datasets spanning 50 years and 25,000 participants to identify therapeutic targets.
Summary from 10-K filed 2026-03-24
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Collaboration revenue | 9 | 0 | — | |
| Research and development | 74 | 59 | 34 | |
| General and administrative | 28 | 19 | 15 | |
| Total operating expenses | 102 | 78 | 48 | |
| Loss from operations | −93 | −78 | −48 | |
| Interest expense | −697,000 | −2 | −8 | |
| Interest and other income (expense), net | 13 | 10 | 2 | |
| Gain (loss) from changes in fair value of warrants | −214,000 | 73,000 | — | |
| Loss on extinguishment of debt | 0 | −250,000 | — | |
| Total other income (expense), net | 12 | 7 | −15 | |
| Net loss | −81 | −71 | −64 | |
| Net loss per share attributable to common stockholders, Basic | −2.24 | −6.63 | −38.17 | |
| Net loss per share attributable to common stockholders, Diluted | −2.24 | −6.63 | −38.17 | |
| Weighted-average common shares outstanding, basic | 36 | 11 | 2 | |
| Weighted-average common shares outstanding, dilutive | 36 | 11 | 2 | |
| Unrealized holding gains on available-for-sale investments | 122,000 | 0 | — | |
| Foreign currency translation adjustment | −89,000 | 81,000 | −3,000 | |
| Total other comprehensive income | 33,000 | 81,000 | — | |
| Total comprehensive loss | −81 | −71 | −64 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 189 | 354 | 22 | — | |
| Marketable securities, current | 92 | 0 | — | — | |
| Accounts receivable | 769,000 | 0 | — | — | |
| Prepaid expenses and other current assets | 5 | 3 | 349,000 | — | |
| Total current assets | 287 | 357 | 25 | — | |
| Investments | 100,000 | 100,000 | 100,000 | — | |
| Marketable securities | 4 | 0 | — | — | |
| Property and equipment, net | 963,000 | 591,000 | 323,000 | — | |
| Operating lease right-of-use assets | 3 | 200,000 | 195,000 | — | |
| Other assets | 216,000 | 240,000 | — | — | |
| Total assets | 295 | 358 | 26 | — | |
| Accounts payable | 3 | 2 | 2 | — | |
| Accrued expenses and other current liabilities | 8 | 12 | 8 | — | |
| Current portion of term loan | 3 | 6 | 6 | — | |
| Operating lease liabilities, current | 582,000 | 202,000 | 194,000 | — | |
| Deferred revenue, current | 6 | 8 | — | — | |
| Total current liabilities | 20 | 28 | 58 | — | |
| Deferred revenue | 0 | 5 | — | — | |
| Term loan | 0 | 3 | 8 | — | |
| Warrant liability | 370,000 | 156,000 | 229,000 | — | |
| Operating lease liabilities | 2 | 0 | — | — | |
| Total liabilities | 23 | 35 | 67 | — | |
| Commitments and Contingencies (Note 8) | — | — | — | — | |
| Preferred stock, $0.00001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31,2024; no shares issued and outstanding as of December 31, 2025 and December 31, 2024 | 0 | 0 | — | — | |
| Common stock, $0.00001 par value; 500,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 37,386,908 and 35,850,037 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 0 | 0 | 0 | — | |
| Additional paid-in-capital | 605 | 576 | 8 | — | |
| Accumulated other comprehensive income | 278,000 | 245,000 | 164,000 | — | |
| Accumulated deficit | −333 | −253 | −182 | — | |
| Total stockholders' equity | 272 | 323 | −173 | −113 | |
| Total liabilities and stockholders' equity | 295 | 358 | 26 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Net loss | −81 | −71 | −64 | |
| Stock-based compensation expense | 12 | 7 | 3 | |
| Depreciation expense | 213,000 | 167,000 | 162,000 | |
| Non-cash interest expense | 163,000 | 1 | 7 | |
| Non-cash lease expense | 125,000 | 3,000 | — | |
| (Gain) loss from changes in fair value of warrants | 214,000 | −73,000 | — | |
| Loss on disposal of property and equipment | 23,000 | 55,000 | — | |
| Accretion of net investment discounts | −2 | — | — | |
| Accounts receivable | −769,000 | 0 | — | |
| Prepaid expenses and other current assets | −2 | −2 | 37,000 | |
| Other Assets | 24,000 | −240,000 | — | |
| Accounts payable | 788,000 | 6,000 | −393,000 | |
| Accrued expenses and other current liabilities | −3 | 5 | 4 | |
| Deferred grant income | 0 | −3 | 3 | |
| Deferred revenue | −7 | 13 | — | |
| Net cash used in operating activities | −82 | −52 | −37 | |
| Purchase of property and equipment | −719,000 | −366,000 | −166,000 | |
| Purchases of marketable securities | −155 | 0 | — | |
| Maturities of marketable securities | 60 | 0 | — | |
| Net cash used in investing activities | −95 | −366,000 | −266,000 | |
| Proceeds from Series D issuance | 0 | 170 | — | |
| Issuance costs paid on Series D issuance | 0 | −542,000 | — | |
| Proceeds from initial public offering, net of underwriting discounts and commissions | 0 | 212 | — | |
| Issuance costs paid on initial public offering and private placement | 0 | −5 | — | |
| Proceeds from issuance of common shares through private placement, net of placement agent fees | 0 | 10 | — | |
| Proceeds from issuance of common stock through at-the-market facility, net of commissions | 17 | 0 | — | |
| Issuance costs paid on at-the market offering | −64,000 | 0 | — | |
| Deferred offering costs paid | −336,000 | 0 | — | |
| Term loan principal payments | −6 | −6 | −1 | |
| Proceeds from issuance of common shares upon stock option exercises | 714,000 | 634,000 | 4,000 | |
| Net cash provided by financing activities | 11 | 381 | 35 | |
| Effect of changes in exchange rate on cash and cash equivalents | −87,000 | 81,000 | — | |
| Net increase (decrease) in cash and cash equivalents | −165 | 329 | −3 | |
| Unpaid purchases of property and equipment | 13,000 | 124,000 | — | |
| Conversion of convertible promissory notes into Series D-1 redeemable convertible preferred stock | 0 | 41 | — | |
| Conversion of redeemable convertible preferred stock into common stock upon initial public offering | 0 | 343 | — | |
| Cash paid for interest | 611,000 | 1 | 1 | |
| Unpaid equity issuance costs included in accounts payable and accrued expenses | 123,000 | 0 | — | |
| Right-of-use assets obtained in exchange for lease obligation | 3 | 282,000 | 407,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is BioAge Labs, Inc.'s CIK number?
BioAge Labs, Inc.'s SEC CIK number is 0001709941 (1709941). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find BioAge Labs, Inc.'s SEC filings?
All of BioAge Labs, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did BioAge Labs, Inc. last report earnings?
BioAge Labs, Inc. (BIOA) most recently filed an earnings 8-K with the SEC on May 8, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-213472). This is BioAge Labs, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is BioAge Labs, Inc.'s most recent earnings 8-K?
BioAge Labs, Inc.'s latest earnings 8-K (Item 2.02) was filed May 8, 2026 under accession 0001193125-26-213472. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View BioAge Labs, Inc.'s latest earnings 8-K →
Look up any company's CIK number →